Skip to main content

Table 1 Summary of mean ABC (antibody binding capacity) values and ADCC activities of GBR 401 and RTX on primary B malignancies and B cell lines

From: A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

Target cells

Antigenic CD19 sites

Antigenic CD20 sites

EC50GBR 401 (μg/ml)

EC50RTX (μg/ml)

EC50GBR 401 (F) (μg/ml)

Average max killing GBR 401 (%)

Average max killing RTX (%)

Average max killing GBR 401 (F) (%)

Raji

57 100 (11 000)

100 400 (13 200)

0.0012

0.012#

0.08#

80

60

30#

Ramos

50 700 (6700)

160 600 (29 700)

0.0009

0.016

 

60

60

 

SU-DHL-6

30 000 (4800)

822 400 (41 000)

0.0008

0.0045

 

50

40

 

Namalwa

37 900 (4500)

1 700 (1200)

0.002

NA

 

60

15

 

B-CLL

10 520 (4140)

3 230 (2000)

0.0016 (0.003)

0.8*** (1.1)

 

60.04 (16.9)

44.54*** (15.1)

 

Lymphoma

  

0.015

0.15**

 

32

32

 
  1. The table displays ADCC values obtained with at least 4 different NK cell donors for Raji, Ramos, SU-DHL-6 and Namalwa cells. The EC50 values are given in μg/mL (SD). The average max killing is given in % (SD). Antigenic CD19 and CD20 sites values are mean (SD). NA, Not applicable. Stars or # indicate statistical significance compared to GBR 401 value (*< .05, **< .01, ***< .001 by student t test, #< .05 by Wilcoxon ranked test).